Exclusive Interview with Miao Zhenwei of Acrux Therapeutics: Ambitions Behind a NewCo Deal
The Next Chapter of China’s NewCo Model
Time：
2026-05-15 17:57
Author：
xieyijun
GSK in Transition: Perfect, It’s Chinese Innovative Drugs
Targeting £40 billion in revenue
Time：
2026-05-15 08:22
Author：
xieyijun
End of a Chaotic Tenure: FDA Commissioner Steps Down After 14 Months
The Makary Era Ends: Is FDA’s Turmoil Over?
Time：
2026-05-14 08:31
Author：
xieyijun
After Daiichi Sankyo’s ADC Misstep
Where will the next blockbuster conjugate drug emerge?
Time：
2026-05-13 08:30
Author：
xieyijun
Pharma R&D Spending TOP 15: Global vs. Domestic
Time：
2026-05-12 17:56
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务